Novo Nordisk Expands Share Repurchase Programme With DKK 11.2 Billion Buyback Plan
Novo Nordisk Expands Share Repurchase Programme With DKK 11.2 Billion Buyback Plan
Novo Nordisk A/S has announced new details of its ongoing share repurchase programme, confirming that the Danish healthcare company has begun buying back B shares under a plan worth up to DKK 11.2 billion. The programme started on 6 May 2026 and is scheduled to run until 1 February 2027.
Key Details of the Programme
The buyback forms part of Novo Nordiskâs broader plan to repurchase shares worth up to DKK 15 billion over a 12-month period beginning on 4 February 2026. The company said the programme follows European market rules, including the Market Abuse Regulation and Safe Harbour Rules, which are designed to ensure transparency and orderly trading.
Between 6 May and 13 May 2026, Novo Nordisk bought back 1,239,849 B shares for a total value of about DKK 369.7 million. The daily purchases included transactions at average prices ranging from about DKK 290.45 to DKK 302.39 per share.
Accumulated Buybacks Since February
As of 13 May 2026, Novo Nordisk had repurchased a total of 15,999,028 B shares since the broader programme began on 4 February 2026. These shares were bought at an average price of DKK 260.62 per B share, representing a total transaction value of approximately DKK 4.17 billion.
Treasury Shares and Share Capital
Following the latest transactions, Novo Nordisk said it owns 33,184,329 B shares as treasury shares. This equals around 0.7% of the companyâs total share capital. Novo Nordiskâs total number of A and B shares, including treasury shares, stands at 4,465,000,000.
Why Share Repurchases Matter
A share repurchase programme is a common way for a listed company to return capital to shareholders. By buying back its own shares, a company can reduce the number of shares available in the market. This may support earnings per share and can signal managementâs confidence in the companyâs long-term outlook.
For Novo Nordisk, the programme also reflects disciplined capital management. The company remains one of the worldâs leading healthcare groups, with a strong focus on diabetes care, obesity treatment, and other serious chronic diseases.
About Novo Nordisk
Novo Nordisk is headquartered in BagsvÃĶrd, Denmark, and was founded in 1923. The company employs about 67,900 people across 80 countries and markets its products in around 170 countries. Its B shares are listed on Nasdaq Copenhagen under the ticker Novo-B, while its ADRs trade on the New York Stock Exchange under NVO.
Investor and Market Impact
The latest announcement gives investors a clearer view of Novo Nordiskâs capital return strategy for 2026. While the buyback does not change the companyâs operating business directly, it can influence investor sentiment by showing that management is actively managing shareholder value.
The company also noted that separate transactions linked to incentive programmes resulted in a net transfer of 204,498 shares from Novo Nordisk during the same reporting period. These shares were not part of the Safe Harbour repurchase programme.
Conclusion
Novo Nordiskâs latest share repurchase update highlights continued progress under its DKK 15 billion capital return plan. With more than DKK 4.16 billion already spent since February 2026, the company is moving steadily through its buyback programme while maintaining transparency for investors and the market.
#SlimScan #GrowthStocks #CANSLIM